HW091077
Phase 2Small molecule
HW091077 is one of 13 small molecule programs targeting Chronic Cough. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Chronic Cough
#DrugCompanyPhaseTrials
1Singulair
OOrganon and Co
Approved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Nucala
GGlaxo Dba Glaxosmithkline
Approved
Quietus
Merck & Co.Phase 3
Pulmicort
SSalix
Preclinical
NOC-110
NNocion Therapeutics
Phase 2
HW091077
HHubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase 2
HS-10383
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Cough1 trial
A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC).
Not yet recruiting·HHubei Bio-Pharmaceutical Industrial Technological Institute Inc.·Phase 2·NCT07483489·180 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HW091077. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details